Get started
Author

Sylvain Carras

Observed names: Carras Sylvain, Carras, Sylvain, S Carras, S. CARRAS, S. Carras
Observed institutions: Lyon 1 Université, Centre National de la Recherche Scientifique, Inserm, Université Joseph Fourier, Université de Lyon, Centre Hospitalier Universitaire de Grenoble, Hospices Civils de Lyon, Centre Léon Bérard, Hôpital Lyon Sud, Centre de Recherche en Cancérologie de Lyon, Établissement Français du Sang, Translational Innovation in Medicine and Complexity, Institut pour l'avancée des biosciences, Hôpital Albert Michallon, Pôle de recherche et d'enseignement supérieur Université de Grenoble, Heinrich Heine University Düsseldorf, Université Grenoble Alpes
ORCID: 0000-0002-0796-7914
Observed ORCID: 0000-0002-0796-7914
OpenAlex ID: A5074554121
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
2022 · Emmanuel Bachy, Steven Le Gouill, et al. · Nature Medicine · 408
PDF
Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry
2023 · Jean Lemoine, Emmanuel Bachy, et al. · Blood Advances · 87
PDF
Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells
2021 · Pierre Sesques, Jérémie Tordo, et al. · Clinical Nuclear Medicine · 72
Primary cardiac lymphoma: diagnosis, treatment and outcome in a modern series
2016 · Sylvain Carras, Françoise Berger, et al. · Hematological Oncology · 69
PFMG2025–integrating genomic medicine into the national healthcare system in France
2025 · Caroline Abadie, Aldja Abderrahmane, et al. · The Lancet Regional Health - Europe · 59
PDF
First‐line treatment of double‐hit and triple‐hit lymphomas: Survival and tolerance data from a retrospective multicenter French study
2020 · Marie‐Charlotte Laude, Laure Lebras, et al. · American Journal of Hematology · 57
PDF
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma
2018 · Rémy Gressin, Nicolas Daguindau, et al. · Haematologica · 47
PDF
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma
2024 · Pierre Sesques, Amy A. Kirkwood, et al. · Journal of Hematology & Oncology · 40
PDF
Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC
2016 · B Tessoulin, P Ceballos, et al. · Bone Marrow Transplantation · 33
Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study)
2024 · Samuel Vic, Jean-Baptiste Thibert, et al. · Blood Advances · 30
Frontline Therapy with the Ribvd Regimen Elicits High Clinical and Molecular Response Rates and Long PFS in Elderly Patients Mantle Cell Lymphoma (MCL); Final Results of a Prospective Phase II Trial By the Lysa Group
2014 · Remy Gressin, Mary Callanan, et al. · Blood · 22
Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric non-human immunodeficiency virus-associated plasmablastic lymphoma
2015 · Sylvain Carras, Caroline Regny, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 21
Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy
2024 · Vincent Camus, Roch Houot, et al. · Blood Advances · 20
Outcomes of patients with relapsed or refractory primary mediastinal B‐cell lymphoma treated with anti‐CD19 CAR‐T cells: CARTHYM, a study from the French national DESCAR‐T registry
2025 · Jean Galtier, Charles Mesguich, et al. · HemaSphere · 18
PDF
Alemtuzumab for Severe Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease
2014 · Mathieu Meunier, Claude Eric Bulabois, et al. · Transplantation and Cellular Therapy · 18
PDF
Real World Data of Axicabtagene Ciloleucel As Second Line Therapy for Patients with Large B Cell Lymphoma: First Results of a Lysa Study from the French Descar-T Registry
2023 · Gabriel Brisou, Guillaume Cartron, et al. · Blood · 14
Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study
2012 · Patrice Chevallier, Nelly Robillard, et al. · Blood · 14
Adult patients with de novo acute myeloid leukemia show a functional deregulation of redox balance at diagnosis which is correlated with molecular subtypes and overall survival
2019 · Julie Mondet, Caroline Lo Presti, et al. · Haematologica · 13
PDF
Extracorporeal photopheresis as a curative treatment strategy in non epidermotropic T-cell lymphoma and large granular lymphocyte leukemia
2012 · F. Garban, S. Carras, et al. · Annals of Oncology · 13
PDF
KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma
2023 · Amandine Decroos, Morgane Cheminant, et al. · Haematologica · 12
PDF
Dramatic Efficacy of Ibrutinib in a Schnitzler Syndrome Case with Indolent Lymphoma
2021 · Fabien Claves, Romane Siest, et al. · Journal of Clinical Immunology · 11
Outcome of high-grade B-cell lymphoma compared with other large B-cell lymphoma after CAR-T rescue: a DESCAR-T LYSA study
2025 · Xavier Phina-Ziebin, Emmanuel Bachy, et al. · Blood Advances · 10
Clinical use of circulating tumor DNA analysis in patients with lymphoma
2024 · Bettina Bisig, Karine Lefort, et al. · Human Pathology · 10
Large B-cell lymphomas with CCND1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphoma
2024 · Ece Özoğul, Anna Montaner, et al. · Blood Cancer Journal · 10
PDF
Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry
2022 · Jean Lemoine, Emmanuel Bachy, et al. · Blood · 10
Works count: 110
Citation count: 1,281
H-index: 15
I10-index: 26
Year
Topic
Type